Lemuel Martinez Bonilla, MD
Infectious Disease · Manati, PRNPI 1073761193
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (40.8%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Merck accounts for 77.1% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $3,765 and has fallen 96.7% since, to $125 in 2025.
Across 26 payments — averaging $212.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$4K
- AbbVie$360
- Johnson & Johnson$224
- Paratek Pharmaceuticals, Inc.$139
- Verity Pharmaceuticals Inc.$123
- Shionogi Inc$116
- plus $300 from 5 others
What the payments were for
- Consulting fees$2,00036%
- Speaking & faculty fees$2,25041%
- Food & beverage$1,26223%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 4 | $4,250 |
| AbbVie(2 entities) | 8 | $360 |
| Johnson & Johnson | 4 | $224 |
| Paratek Pharmaceuticals, Inc. | 1 | $139 |
| Verity Pharmaceuticals Inc. | 1 | $123 |
| Shionogi Inc | 1 | $116 |
| Edwards Lifesciences | 1 | $103 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $71 |
| E.r. Squibb & Sons, L.L.C. | 2 | $49 |
| PBG Puerto Rico LLC | 2 | $49 |
| Chiesi USA, Inc. | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PNEUMOVAX 23$1,125
- ZERBAXA$1,125
- NUZYRA$139
- EMBLAVEO$125
- TRELSTAR$123
- XARELTO$119
- Fetroja$116
- ClearSight System$103
- AVYCAZ$100
How this compares
$5,512 in reported general payments places this provider in the 85th percentile of 127 infectious disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other infectious disease in Manati
- Jorge Santana BagurManati$180K
- Marielys Otero MaldonadoManati$3K
- Marisel Bosques RosadoHato Rey$247K
- Francisco AlvaradoCaguas$69K
- Jorge Bertran-PasarellHato Rey$64K
- Joel Munoz CoreanoBayamon$59K
- Vanessa Olivo EchavarrySan Juan$41K
- Carlos Guzman OrtizAibonito$38K
- Angeles Rodriguez RosaSan Juan$27K
- Miguel Colon PerezSan Juan$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.